C4 Therapeutics Inc
NASDAQ:CCCC

Watchlist Manager
C4 Therapeutics Inc Logo
C4 Therapeutics Inc
NASDAQ:CCCC
Watchlist
Price: 4.72 USD -7.99% Market Closed
Market Cap: 327.3m USD
Have any thoughts about
C4 Therapeutics Inc?
Write Note

C4 Therapeutics Inc
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

C4 Therapeutics Inc
Cash Equivalents Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
C4 Therapeutics Inc
NASDAQ:CCCC
Cash Equivalents
$126.6m
CAGR 3-Years
-11%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash Equivalents
$7.3B
CAGR 3-Years
-16%
CAGR 5-Years
-7%
CAGR 10-Years
-1%
Gilead Sciences Inc
NASDAQ:GILD
Cash Equivalents
$5B
CAGR 3-Years
5%
CAGR 5-Years
-12%
CAGR 10-Years
-2%
Amgen Inc
NASDAQ:AMGN
Cash Equivalents
$9B
CAGR 3-Years
-9%
CAGR 5-Years
-5%
CAGR 10-Years
9%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash Equivalents
$6.5B
CAGR 3-Years
1%
CAGR 5-Years
14%
CAGR 10-Years
25%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash Equivalents
$2B
CAGR 3-Years
-16%
CAGR 5-Years
8%
CAGR 10-Years
12%

See Also

What is C4 Therapeutics Inc's Cash Equivalents?
Cash Equivalents
126.6m USD

Based on the financial report for Dec 31, 2023, C4 Therapeutics Inc's Cash Equivalents amounts to 126.6m USD.

What is C4 Therapeutics Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
28%

Over the last year, the Cash Equivalents growth was 325%. The average annual Cash Equivalents growth rates for C4 Therapeutics Inc have been -11% over the past three years , 28% over the past five years .

Back to Top